Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Ocular Melanoma, Uveal Melanoma
Interventions: Melphalan/HDS; Combination Product
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 9
States / cities: Tucson, Arizona • Palo Alto, California • Tampa, Florida + 6 more

Conditions: Knee Osteoarthritis, Osteo Arthritis Knee
Interventions: Microfragmented Adipose Tissue, Corticosteroid; Device · Drug
Lead sponsor: Lipogems International spa; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 18
States / cities: Encinitas, California • Redwood City, California • Gulf Breeze, Florida + 14 more

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 81
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 70 more

Conditions: Pancreatic Pseudocyst(s)
Interventions: AXIOS Stent & Delivery System; Device
Lead sponsor: Xlumena, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 3 more

Conditions: Hepatitis C Virus
Interventions: Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more

Conditions: Soft Tissue Sarcoma
Interventions: ADI PEG20, Placebo; Drug · Other
Lead sponsor: Polaris Group; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 21 more

Conditions: Rhinoconjunctivitis
Interventions: Cat-PAD, Placebo; Drug
Lead sponsor: Circassia Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 52
States / cities: Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more

Conditions: COVID-19
Interventions: Apixaban 2.5 MG, Apixaban 5MG, Aspirin, Placebo; Drug
Lead sponsor: Frank C Sciurba; Other
Eligibility: 40 Years to 80 Years
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 71
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 51 more

Conditions: Acute Myocardial Infarction, STEMI
Interventions: FDY-5301, Placebo; Drug · Other
Lead sponsor: Faraday Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • The Bronx, New York

Conditions: Infections, Meningococcal
Interventions: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 704 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 36
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more

Conditions: Hepatitis C, Chronic
Interventions: peginterferon alfa-2a [Pegasys], ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 7
States / cities: San Francisco, California • Farmington, Connecticut • Honolulu, Hawaii + 4 more

Conditions: Breast
Interventions: QT Ultrasound scan; Device
Lead sponsor: QT Ultrasound LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 755 participants
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Long Beach, California • Novato, California

Conditions: Insulin-like Growth Factor-1 Deficiency
Interventions: NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 5 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Cancer
Interventions: immunological diagnostic method, physiologic testing; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Dental Caries
Interventions: C16G2 Gel, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Healthy Volunteers
Interventions: PF614, Naltrexone Hydrochloride, OxyContin; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
Interventions: Radiation therapy; Radiation
Lead sponsor: UMC Utrecht; Other
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Houston, Texas • Milwaukee, Wisconsin

Conditions: Eastern Equine Encephalitis
Interventions: Inactivated, Dried, TSI-GSD 104, EEE; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Head and Neck Cancer, Human Papilloma Virus
Interventions: MEDI0457, CELLECTRA®5P device, Durvalumab; Drug · Device
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 14
States / cities: San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more

Conditions: Acute Ischemic Stroke
Interventions: LT3001 Drug Product, Placebo; Drug
Lead sponsor: Lumosa Therapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia, Parkinson Disease, Multiple Sclerosis, TBI
Interventions: Boston Cognitive Assessment (BoCA); Diagnostic Test
Lead sponsor: Alzheimer's Light LLC; Industry
Eligibility: 50 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COPD
Interventions: myAirvo3, Pulse oximeter; Device
Lead sponsor: Temple University; Other
Eligibility: 30 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more

Conditions: Migraine
Interventions: divalproex sodium; Drug
Lead sponsor: Abbott; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: North Chicago, Illinois

Search by objective public record fields.

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee Osteoarthritis

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

AXIOS Stent & Delivery System Study

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Phase III Cat-PAD Study

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

A Study of Acute Myocardial Infarction Using FDY-5301

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.

Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

Longitudinal Cognitive Assessment by BoCA

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents